OKYO First Treatment for Neuropathic Corneal Pain?

OKYO Pharma (NASDAQ: OKYO), a clinical-stage biopharmaceutical company, announced that CEO Gary S. Jacob will present at the Bio International Convention 2025 in Boston. The presentation will focus on urcosimod, the company's lead clinical drug candidate being developed to treat neuropathic corneal pain (NCP). NCP is a severe ocular condition affecting tens of thousands globally, causing chronic and severe eye discomfort, with no current FDA-approved treatment. The presentation will take place during the convention scheduled for June 16-19, 2025, at the Boston Convention & Exhibition Center.

https://www.stocktitan.net/news/OKYO/okyo-pharma-to-present-at-the-bio-international-6wcanvqh0edn.html